Enlivex Therapeutics Ltd.: Phase 2 study completed, 134 enrolled (Osteoarthritis, Knee)
Enlivex Therapeutics Ltd.: Phase 2 study completed, 134 enrolled (Osteoarthritis, Knee). Its enrollment of 134 is above the median of 80 (67th percentile). Dated 1 day ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 134 · 67th percentile of 9,177 ClinicalTrialStartPulse records · 1.7x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Enlivex Therapeutics Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of Intra-articular Allocetra in Knee Osteoarthritis |
| NCT ID | NCT06233474 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Osteoarthritis, Knee |
| Intervention types | drug, other |
| Target enrollment | 134 |
| Site countries | Denmark, Israel, Moldova |
| Posted | 2024-01-31 |
| Planned start | 2024-01-26 |
| Event | Completed |
| Event date | 2026-10-15 |
| Last update posted | 2026-11-04 |
| enrollment percentile | 67th of 9,177 (median 80, 1.7x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Enlivex Therapeutics Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Enlivex Therapeutics + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-11-04
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Enlivex Therapeutics Ltd. and 6,823 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,823
- Enlivex Therapeutics Ltd.'s enrollment: 67th percentile of 9,177 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,364,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 134 participants planned.
What is the ClinicalTrialStartPulse record for Enlivex Therapeutics Ltd.?
Enlivex Therapeutics Ltd.'s Phase 2 study (NCT06233474) in Osteoarthritis, Knee, first posted 2024-01-31: completed (2026-10-15), in an update posted 2026-11-04.
How does Enlivex Therapeutics Ltd. compare to other ClinicalTrialStartPulse records?
Its enrollment of 134 sits in the upper half (67th percentile) of 9,177 records; the median is 80. It is fresh: dated 1 day ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Enlivex Therapeutics Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Enlivex Therapeutics Ltd. | NONUS | 134 | 67th | 2026-11-04 |
| Genfleet Therapeutics (Shanghai) Inc. | NONUS | 150 | 71st | 2026-11-04 |
| Tortugas Neuroscience, Inc. | NONUS | 100 | 60th | 2026-11-04 |
| GlaxoSmithKline | NONUS | 279 | 82nd | 2026-11-04 |
Related records
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: Outside the US only
How to monitor Enlivex Therapeutics Ltd. and peer phase 2 records
Get new ClinicalTrialStartPulse records like Enlivex Therapeutics Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.